TANGO2 Deficiency Disorder: Phenotypic Heterogeneity Beyond Metabolic and Cardiac Crises

Background: TANGO2 deficiency disorder (TDD) is a rare autosomal recessive multisystem disorder caused by biallelic pathogenic variants in the Transport and Golgi Organization 2 (TANGO2) gene. First recognized as a distinct clinical entity in 2016, TDD remains underdiagnosed due to its broad phenotypic spectrum, which ranges from neurodevelopmental abnormalities and paroxysmal neurological episodes to life-threatening metabolic crises characterized by rhabdomyolysis, encephalopathy, QTc prolongation, and ventricular arrhythmias. Recognition may be particularly challenging in patients without the classical metabolic or cardiac manifestations. We describe three patients with TDD, highlighting phenotypic heterogeneity, early neurological manifestations, and diagnostic challenges.

Case Presentation Summary: Patient 1: A male patient with a family history of a sister with SNX14-associated cerebellar ataxia presented at 4 months of age with acquired microcephaly and poor weight gain, followed by developmental delay. By young adulthood, he had developed severe intellectual disability, epilepsy, hypothyroidism, dysmetria, bradykinesia, and dystonic laughter. No paroxysmal episodes, metabolic decompensations, or cardiac involvement were reported. Muscle biopsy and metabolic investigations were unremarkable, and targeted testing for the familial SNX14 variant was negative. Exome sequencing established the diagnosis of TDD at 28 years of age.

Patient 2: A male patient presented during infancy with global developmental delay, including poor head control and delayed language development. From 12 months of age, he experienced recurrent episodes of cognitive and motor deterioration triggered by fever or exertion, followed by transient loss of previously acquired skills. No dysmorphic features or growth abnormalities were observed. He subsequently developed moderate intellectual disability, pyramidal signs affecting all four limbs, and orobuccal apraxia. Brain MRI, metabolic investigations, and previous genetic studies, including chromosomal microarray analysis, were nondiagnostic. Next-generation sequencing using a multigene panel for intellectual disability identified an intragenic deletion and a pathogenic splice-site variant in TANGO2 in compound heterozygosity, establishing the diagnosis at 13 years of age.

Patient 3: A previously healthy female patient developed recurrent episodes of hypotonia, ataxia, and dysmetria from 18 months of age, occasionally associated with claudication and hypersalivation, without intercurrent illness. She also presented with lower-limb pyramidal signs and mild dysmetria. Brain MRI showed nonspecific white matter abnormalities. No rhabdomyolysis or cardiovascular involvement was reported. Extensive metabolic investigations and a recurrent ataxia gene panel were nondiagnostic. By 10 years of age, she had been diagnosed with intellectual and language developmental disorder and hypothyroidism. Nonspecific craniofacial dysmorphic features were noted. Array comparative genomic hybridization established the diagnosis of TDD at 12 years of age.

Learning Points Discussion: These cases illustrate the broad phenotypic spectrum and marked clinical heterogeneity of TDD, for which no established genotype–phenotype correlation has been identified, highlighting that the absence of rhabdomyolysis episodes or cardiac involvement does not exclude the diagnosis. Paroxysmal neurological episodes may represent an important diagnostic clue, particularly when associated with otherwise unexplained neurodevelopmental impairment, epilepsy, movement abnormalities, or hypothyroidism. Timely access to comprehensive genomic testing may reduce diagnostic delay. Recognition of predominantly neurodevelopmental and episodic neurological phenotypes is essential to prompt molecular testing and enable appropriate multidisciplinary surveillance and preventive management.